Phathom Pharmaceuticals (PHAT)Chief Operating Officer sold ~$52K

~$52K

Approx. value · 7,886 sh @ $6.59

233K

Holds after · shares reported

Traded

Jan 21, 2025

Filed

Jan 23, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Dec 13, 2024Insider · 2 peopleInsiders: 2 purchases (~$180K)
2. Dec 19, 2024Insider · 2 peopleInsiders: 2 sales (~$19K)
3. Jan 21, 2025 · this disclosureInsiderOfficer sold ~$52K of PHAT shares in the open market

What came next

1. Jan 21, 2025Insider · 2 peopleInsiders: 2 sales (~$169K)
2. Mar 13, 2025InsiderDirector purchased ~$44K of PHAT shares in the open market
3. Apr 7, 2025InsiderCFO sold ~$17K of PHAT shares in the open market
4. May 6, 2025InsiderDirector purchased ~$13K of PHAT shares in the open market
5. May 7, 2025InsiderDirector purchased ~$12K of PHAT shares in the open market
6. May 9, 2025Insider · 1 personInsiders: 2 purchases (~$115K)
7. May 12, 2025InsiderDirector purchased ~$38K of PHAT shares in the open market
8. May 13, 2025InsiderDirector purchased ~$3.5K of PHAT shares in the open market
9. May 14, 2025InsiderDirector purchased ~$21K of PHAT shares in the open market

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Phathom Pharmaceuticals

OQRO holds no insider, Congress, fund or contract record for Phathom Pharmaceuticals dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its PHAT page.

Other recent filings by Azmi Nabulsi, Chief Operating Officer

• SEC Form 4 at Phathom Pharmaceuticals (PHAT)Dec 20, 2024

The full history of Azmi Nabulsi, Chief Operating Officer is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Phathom Pharmaceuticals

• SEC Form 13F-HRMay 15, 2026
• SEC Form 13F-HRFeb 17, 2026
• SEC Form 13F-HROct 20, 2025
• SEC Form 4Sep 9, 2025
• SEC Form 13F-HRAug 14, 2025
• SEC Form 13F-HRAug 7, 2025

Everything OQRO holds on this company is on its PHAT page.